These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. The KCa3.1 blocker TRAM34 reverses renal damage in a mouse model of established diabetic nephropathy. Huang C; Zhang L; Shi Y; Yi H; Zhao Y; Chen J; Pollock CA; Chen XM PLoS One; 2018; 13(2):e0192800. PubMed ID: 29425253 [TBL] [Abstract][Full Text] [Related]
8. Combination of aspirin with telmisartan suppresses the augmented TGFbeta/smad signaling during the development of streptozotocin-induced type I diabetic nephropathy. Mulay SR; Gaikwad AB; Tikoo K Chem Biol Interact; 2010 Apr; 185(2):137-42. PubMed ID: 20223228 [TBL] [Abstract][Full Text] [Related]
9. The role and mechanism of K Ma XZ; Pang ZD; Wang JH; Song Z; Zhao LM; Du XJ; Deng XL Exp Cell Res; 2018 Aug; 369(2):208-217. PubMed ID: 29792849 [TBL] [Abstract][Full Text] [Related]
10. Targeted inhibition of KCa3.1 channel attenuates airway inflammation and remodeling in allergic asthma. Yu ZH; Xu JR; Wang YX; Xu GN; Xu ZP; Yang K; Wu DZ; Cui YY; Chen HZ Am J Respir Cell Mol Biol; 2013 Jun; 48(6):685-93. PubMed ID: 23492185 [TBL] [Abstract][Full Text] [Related]
11. K Pang ZD; Wang Y; Wang XJ; She G; Ma XZ; Song Z; Zhao LM; Wang HF; Lai BC; Gou W; Du XJ; Deng XL FASEB J; 2019 Dec; 33(12):14760-14771. PubMed ID: 31690106 [TBL] [Abstract][Full Text] [Related]
12. Evolution of treatment for diabetic nephropathy: historical progression from RAAS inhibition and onward. Blumenthal SS Postgrad Med; 2011 Nov; 123(6):166-79. PubMed ID: 22104465 [TBL] [Abstract][Full Text] [Related]
13. Transforming growth factor-β/Smad signalling in diabetic nephropathy. Lan HY Clin Exp Pharmacol Physiol; 2012 Aug; 39(8):731-8. PubMed ID: 22211842 [TBL] [Abstract][Full Text] [Related]
14. Diabetic nephropathy: where hemodynamics meets metabolism. Forbes JM; Fukami K; Cooper ME Exp Clin Endocrinol Diabetes; 2007 Feb; 115(2):69-84. PubMed ID: 17318765 [TBL] [Abstract][Full Text] [Related]
15. Potential for peroxisome proliferator-activated receptor-gamma agonists in progression: beyond metabolism. Fogo AB Curr Opin Nephrol Hypertens; 2008 May; 17(3):282-5. PubMed ID: 18408479 [TBL] [Abstract][Full Text] [Related]
16. RAGE- and TGF-beta receptor-mediated signals converge on STAT5 and p21waf to control cell-cycle progression of mesangial cells: a possible role in the development and progression of diabetic nephropathy. Brizzi MF; Dentelli P; Rosso A; Calvi C; Gambino R; Cassader M; Salvidio G; Deferrari G; Camussi G; Pegoraro L; Pagano G; Cavallo-Perin P FASEB J; 2004 Aug; 18(11):1249-51. PubMed ID: 15180953 [TBL] [Abstract][Full Text] [Related]
17. Advanced glycation end products activate Smad signaling via TGF-beta-dependent and independent mechanisms: implications for diabetic renal and vascular disease. Li JH; Huang XR; Zhu HJ; Oldfield M; Cooper M; Truong LD; Johnson RJ; Lan HY FASEB J; 2004 Jan; 18(1):176-8. PubMed ID: 12709399 [TBL] [Abstract][Full Text] [Related]
18. Role of the TGF-β/BMP-7/Smad pathways in renal diseases. Meng XM; Chung AC; Lan HY Clin Sci (Lond); 2013 Feb; 124(4):243-54. PubMed ID: 23126427 [TBL] [Abstract][Full Text] [Related]